Merck combination suppresses HCV in mono-infected and co-infected patients

An all-oral combination of the hepatitis C virus protease inhibitor MK-5172 and NS5A inhibitor MK-8742, with or without ribavirin, demonstrated promising end-of-treatment viral suppression in people with HIV and HCV co-infection and high cure rates for people with hepatitis C alone, according to findings from the C-WORTHY study presented at recent ... (more)

http://ift.tt/1hP8hxC